Does Vitamin C Help Clonal Hematopoiesis? One Trial, a Split Verdict

Whether vitamin C helps clonal hematopoiesis is no longer only a laboratory question. In 2026 a randomized, placebo controlled trial put a plain 1,000 mg capsule against a dummy pill in people who have this exact blood finding, and followed them for a year. The result is worth reading closely, because it missed the thing it set out to prove and then turned up something nobody had promised.

Clonal hematopoiesis sounds obscure, but it is common with age and it matters. It is a quiet precursor state, a step on the road that in a minority of people leads to blood cancer, and it carries its own raised risk of heart disease along the way. That has made it one of the live topics in longevity medicine.

So a cheap vitamin with a plausible mechanism is exactly the sort of thing people want to hear about. Here is what the trial actually found, and what it did not.

---

What Is Clonal Hematopoiesis?

All of your blood cells descend from a pool of stem cells in the bone marrow. With age, one of those stem cells can pick up a mutation that gives its descendants a slight competitive edge, so a single clone comes to make up a larger and larger share of the blood. When this happens with normal blood counts and no disease, it is called CHIP, clonal hematopoiesis of indeterminate potential. When it comes with unexplained low blood counts, it is CCUS, clonal cytopenia of undetermined significance. Most people who have it never progress. A minority go on to a myelodysplastic syndrome or leukemia, and the group as a whole carries higher cardiovascular risk.

The mutations that drive it tend to hit genes that control how DNA is chemically tagged and read, rather than genes that build proteins directly. One of the most frequent is TET2. This is where vitamin C enters, and not in its familiar role as an antioxidant. The TET enzymes belong to a family of dioxygenases that depend on iron and on alpha-ketoglutarate, another metabolite the longevity field watches closely, and vitamin C acts as a helper that keeps the iron in its working state. Their job is to strip methyl marks off DNA. In a cell carrying a TET2 mutation, that machinery runs at reduced capacity. The idea, built over a decade of bench work, is that flooding the system with vitamin C might prop up the TET activity that remains and nudge the misbehaving clone back toward normal behavior.

---

The Science: Does Vitamin C Help Clonal Hematopoiesis?

The evidence now has one real human trial at its center, called EVITA, and the honest way to read it is to keep what it was designed to show apart from what it stumbled onto.

---

The goal it missed

• The Evidence: EVITA was a phase 2, double blind, placebo controlled trial. It randomized 109 adults who had CCUS or a lower risk myeloid malignancy to 1,000 mg of oral vitamin C a day or a matching placebo for 12 months. The primary endpoint was the rate at which the mutant clone grew. On that measure the two groups were the same, with a difference in median clonal growth rate of -0.016 (95% CI -0.096 to 0.064), p=0.70. Vitamin C did not slow the clone.
• Read the study: Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA

A p value of 0.70 is not a near miss. It is a flat negative on the one question the trial was built to answer. Any headline that says vitamin C shrinks these clones is not describing this trial.

---

The signal nobody was looking for

• The Evidence: In an exploratory, post hoc analysis, the people taking vitamin C lived longer. Overall survival favored the vitamin C group with a hazard ratio of 0.35 (95% CI 0.17 to 0.71, p=0.0025). Serious adverse events were also lower on vitamin C, at 33 percent against 57 percent on placebo.
• Read the study: Results from EVITA, a phase 2 randomized, placebo-controlled trial

Two cautions keep this in proportion. Survival was not what the trial was powered to measure, and an exploratory finding in roughly a hundred people is a hypothesis, not a number to bank on. The clone kept growing in both groups, so whatever drove the survival gap, it was not the mechanism the trial set out to test. The authors say plainly that a phase 3 trial is needed, and they are right.

---

Why vitamin C at all: the TET2 connection

• The Evidence: The rationale comes from the laboratory. In Tet2 deficient mouse blood stem cells, high dose vitamin C restored the chemical tag that the enzyme normally places on DNA, mimicking the effect of switching the gene back on, and it suppressed the growth of human leukemia cells grafted into mice.
• Read the study: Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression

This is why the trial was run, and it is mouse and cell work, not proof that it does the same in people. The distance between a clean mechanism in a dish and a missed endpoint in the clinic is the whole reason trials like EVITA have to happen.

---

A Practical Guide: How to Use It

The dose in the trial was simple: 1,000 mg of plain oral vitamin C, once a day, for a year. That is the amount in a single ordinary ascorbic acid capsule, and it costs a few cents. There is nothing exotic to buy and no liposomal upgrade to chase, because the cheap form is what was tested.

Who should think about it. The people studied all had a diagnosis, CCUS or a lower risk myeloid condition confirmed by a hematologist. If that is you, a daily gram is a reasonable thing to raise at your next appointment, framed honestly as an experiment with an exploratory survival signal behind it rather than a treatment. It does not replace the blood counts your doctor already runs. It would sit alongside them.

Who this is not for. Nobody without a blood diagnosis was studied here. This mirrors nicotinamide for skin cancer, another cheap vitamin whose real trial only ever applied to a narrow, high risk group. If you are healthy and have never had a reason to check your blood, there is no finding in EVITA that applies to you, and taking gram doses to head off a problem you show no sign of is not something this trial supports.

---

Safety and Advice

Vitamin C at 1,000 mg a day is one of the gentler things in this whole field. It is water soluble, and the body sheds most of what it does not use. Even so, EVITA reported more gastrointestinal complaints in the vitamin C group, which fits what high doses are known to do: loose stools and stomach upset are the usual ceiling. If a full gram bothers your gut, taking it with food or splitting the dose helps.

The one caution that deserves naming is kidney stones. Vitamin C is partly converted to oxalate, and high intakes can raise stone risk in people who are already prone to them or who have reduced kidney function. If that is you, clear it with a doctor first. And because this is a blood condition under specialist care, the sensible rule is to tell your hematologist what you are taking rather than adding it quietly, since it can matter for how your results are read.

---

The Bottom Line

Does vitamin C help clonal hematopoiesis? On the question it was designed to answer, whether it slows the mutant clone, EVITA said no, clearly. What it found instead was an unexpected survival advantage that is promising, cheap to act on, and nowhere near proven. For someone already diagnosed with CCUS or CHIP, a 1,000 mg daily capsule is a low cost, low risk thing to discuss with the hematologist who is already watching the numbers. For everyone else, this is a trial about a specific group of patients, not a reason to start taking vitamin C for longevity.

If you have the diagnosis, the concrete next step is a conversation, not a purchase: ask whether a daily gram of vitamin C has a place beside the monitoring you already get, and let the phase 3 trial the authors are calling for settle the rest.

---

This article is for educational purposes only and is not medical advice. Supplements can interact with medications and health conditions, so talk to a qualified healthcare provider before starting anything new.